Gemini Therapeutics, Inc. (GMTX) News

Gemini Therapeutics, Inc. (GMTX): $13.50

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add GMTX to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#133 of 397

in industry

Filter GMTX News Items

GMTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest GMTX News From Around the Web

Below are the latest news stories about GEMINI THERAPEUTICS INC that investors may wish to consider to help them evaluate GMTX as an investment opportunity.

7 Short-Squeeze Stocks for Bold Contrarians to Consider

While market volatility has brough the bears out of hibernation, certain short-squeeze stocks could be a trap for the pessimists.

Josh Enomoto on InvestorPlace | November 21, 2022

Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)

Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today the initiation of AURORA, a Phase 2 clinical study of bitopertin in adults with EPP. Bitopertin is an oral, selective inhibitor of glycine transporter 1 (GlyT1) designed to modulate heme biosynthesis, and has been shown in preclinical studies to reduce accumulation of protoporphyrin IX (

Yahoo | October 31, 2022

Gemini Therapeutics and Disc Medicine Announce Merger Agreement

WAYLAND, Mass. & WATERTOWN, Mass., August 10, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX) ("Gemini") and Disc Medicine, Inc. ("Disc"), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Disc’s pipe

Yahoo | August 10, 2022

Insider Buying: Braden Leonard Just Spent US$75k On Gemini Therapeutics, Inc. (NASDAQ:GMTX) Shares

Even if it's not a huge purchase, we think it was good to see that Braden Leonard, a Gemini Therapeutics, Inc...

Yahoo | April 15, 2022

Gemini Therapeutics Reports 2021 Financial Results

Remote-First-Company/Mass., March 10, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX) today reported financial results for the year ended December 31, 2021.

Yahoo | March 10, 2022

Gemini Therapeutics Provides Corporate Update

Remote-First-Company/Mass., February 28, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring.

Yahoo | February 28, 2022

Gemini Therapeutics Provides GEM103 Program Update

CAMBRIDGE, Mass., January 10, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of GEM103’s clinical development program.

Yahoo | January 10, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!